[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and
Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv Related: [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19 Commentary on Twitter Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced […]
The post [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. appeared first on Links Medicus.
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology
The post ‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo. appeared first on Links Medicus.
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
DARE-19: Dapagliflozin in High-Risk Patients Hospitalized With COVID-19 – American College of Cardiology See also: Dapagliflozin in Respiratory Failure in Patients With COVID-19 – DARE-19 – American College of Cardiology Commentaries on Twitter DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile ? Do not discontinue SGLT2i […]
The post #ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19. appeared first on Links Medicus.
Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions.
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study – The BMJ Commentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can […]
The post Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions. appeared first on Links Medicus.
[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.
BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham Commentaries: Delaying a COVID vaccine’s second dose boosts immune […]
The post [Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age. appeared first on Links Medicus.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial – The Lancet Invited commentary: Convalescent plasma in patients hospitalised with COVID-19 Commentaries on Twitter Convalescent plasma: Yet another example of Don’t guess, don’t gamble Randomize… and learn I’ve heard it said that it was deemed “too difficult” […]
The post RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19. appeared first on Links Medicus.
Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma.
Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library Summary: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma – Cochrane Library
The post Systematic review: Combination fixed‐dose beta-agonist and steroid inhaler as required is clinically effective in adults and adolescents with mild asthma. appeared first on Links Medicus.
RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma – New England Journal of Medicine Commentary: New drug shows promise against tough-to-manage asthma – MedicalXpress
The post RCT: Tezepelumab can reduce exacerbations in adults and adolescents with severe, uncontrolled asthma. appeared first on Links Medicus.
[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.
The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries – The Lancet
The post [Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries. appeared first on Links Medicus.
What is mucormycosis, the fungal infection affecting COVID patients in India?
What is mucormycosis, the fungal infection affecting COVID patients in India? – The Conversation Related: What Is ‘Black Fungus’? And Why Is It Spreading Among India’s COVID Patients? – NPR AND Mucormycosis: The ‘black fungus’ maiming Covid patients in India
The post What is mucormycosis, the fungal infection affecting COVID patients in India? appeared first on Links Medicus.